Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome - Takeaways - MDSpire

Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome

  • By

  • Nour Eldeen Mahmoud Shabaan Ibrahim

  • Mohamed Tarek Mounir Zaki

  • Khaled Ahmed Fouad Abdel Magid

  • Khaled Ahmed Fouad

  • Mina Magued Abdalla Iskandar

  • March 27, 2026

  • 0 min

Share

  • 1

    Diabetic patients have a 2–3 times higher cardiovascular risk, making effective management of acute coronary syndrome crucial.

  • 2

    The study evaluated the impact of transitioning from dual antiplatelet therapy to ticagrelor monotherapy after 3 months on major adverse cardiovascular events.

  • 3

    400 diabetic patients with acute coronary syndrome were randomized into two groups: one receiving ticagrelor monotherapy and the other continuing dual therapy.

  • 4

    Primary outcomes included major adverse cardiovascular events, while secondary outcomes focused on bleeding events classified by BARC criteria.

  • 5

    The study adhered to CONSORT guidelines and aimed to balance the benefits of antiplatelet therapy against the risks of bleeding.

Original Source(s)

Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome

  • by Nour Eldeen Mahmoud Shabaan Ibrahim, Mohamed Tarek Mounir Zaki, Khaled Ahmed Fouad Abdel Magid, Khaled Ahmed Fouad, Mina Magued Abdalla Iskandar

  • March 27, 2026

Related Content

Analysis of factors associated with cognitive impairment in elderly patients hospitalized with chronic heart failure

What RVO May Reveal About Systemic Health

TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.

Magmaris bioresorbable magnesium scaffold in acute coronary syndromes: a systematic review and meta-analysis